Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

November 2022 | 67 pages | ID: N3FFA60BCEF0EN
Global Markets Direct

Abstracts

Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) pipeline Target constitutes close to 16 molecules. Out of which approximately 14 molecules are developed by companies and remaining by the universities/institutes. The latest report GMDHC22228TDB, outlays comprehensive information on the Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Neuronal acetylcholine receptor subunit alpha-7 is a protein encoded by the CHRNA7 gene. After binding to acetylcholine it undergoes an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane. The channel is blocked by alpha-bungarotoxin. The molecules developed by companies in Phase II, Phase I and Preclinical stages are 3, 3 and 8 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Central Nervous System, Cardiovascular, Gastrointestinal, Immunology and Oncology which include indications Alzheimer's Disease, Traumatic Brain Injury, Anxiety Disorders, Cognitive Impairment, Pain, Parkinson's Disease, Schizophrenia, Bipolar Disorder (Manic Depression), Cognitive Disorders, Cognitive Impairment Associated With Schizophrenia (CIAS), Complex Regional Pain Syndrome (Sympathetic Reflex Dystrophy/Reflex Sympathetic Dystrophy), Dementia Associated With Alzheimer's Disease, Inflammation, Ischemic Stroke, Major Depressive Disorder, Mild Cognitive Impairment, Neuropathic Pain (Neuralgia), Panic Disorders, Post-Traumatic Stress Disorder (PTSD), Social Anxiety Disorder (SAD/Social Phobia), Ulcerative Colitis and Unspecified Pain.

Furthermore, this report also reviews key players involved in Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The report provides a snapshot of the global therapeutic landscape for Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7)
• The report reviews Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) targeted therapeutics and enlists all their major and minor projects
• The report assesses Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
• The report summarizes all the dormant and discontinued pipeline projects
• The report reviews latest news and deals related to Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) targeted therapeutics

REASONS TO BUY

• Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Identify and understand the targeted therapy areas and indications for Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7)Identify the use of drugs for target identification and drug repurposing
• Identify potential new clients or partners in the target demographic
• Develop strategic initiatives by understanding the focus areas of leading companies
• Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
• Devise corrective measures for pipeline projects by understanding Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) development landscape
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction
Global Markets Direct Report Coverage
Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Overview
Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Companies Involved in Therapeutics Development
180 Life Sciences Corp
AlphaCognition Inc
AstraZeneca Plc
Bionomics Ltd
Bristol-Myers Squibb Co
DanPET AB
Epigen Biosciences Inc
Lupin Ltd
Merck & Co Inc
Neuro Bio Ltd
Serenity Bioworks Inc
SK Life Science Inc
Vanda Pharmaceuticals Inc
Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Drug Profiles
a7nAchR - Drug Profile
Product Description
Mechanism Of Action
History of Events
ALPHA-1062 - Drug Profile
Product Description
Mechanism Of Action
History of Events
AVL-8168 - Drug Profile
Product Description
Mechanism Of Action
AZD-0328 - Drug Profile
Product Description
Mechanism Of Action
History of Events
BMS-910731 - Drug Profile
Product Description
Mechanism Of Action
BNC-210 - Drug Profile
Product Description
Mechanism Of Action
History of Events
BNC-375 - Drug Profile
Product Description
Mechanism Of Action
History of Events
EPGN-1137 - Drug Profile
Product Description
Mechanism Of Action
History of Events
LL-00066471 - Drug Profile
Product Description
Mechanism Of Action
History of Events
NBP-14 - Drug Profile
Product Description
Mechanism Of Action
History of Events
NS-12877 - Drug Profile
Product Description
Mechanism Of Action
SER-400 - Drug Profile
Product Description
Mechanism Of Action
SKL-20540 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecules to Agonize CHRNA7 for Central Nervous System - Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Antagonize NMDA Receptor and CHRNA7 for Central Nervous System - Drug Profile
Product Description
Mechanism Of Action
VQW-765 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Dormant Products
Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Discontinued Products
Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Product Development Milestones
Featured News & Press Releases
Sep 21, 2022: Bionomics to host KOL wrbinar on BNC210 and social anxiety disorder
Aug 23, 2022: Alpha Cognition reports positive data from Alzheimer’s therapy study
Jun 22, 2022: Alpha Cognition announces positive results from pivotal study with ALPHA-1062 in development for Alzheimer’s Disease
May 10, 2022: Novamind to host Bionomics PREVAIL trial for acute treatment of social anxiety disorder
Apr 06, 2022: Novel Drug from Neuro-Bio effective in a mouse model of Alzheimer’s Disease
Feb 22, 2022: Alpha Cognition announces positive neuroprotection data from pre-clinical study of ALPHA-1062 for Traumatic Brain Injury
Jan 03, 2022: Bionomics initiates phase 2 PREVAIL study of BNC210 for the acute treatment of social anxiety disorder
Dec 06, 2021: Alpha Cognition announce data from pre-clinical study of ALPHA-1062 for traumatic brain injury
Dec 01, 2021: U.S. FDA grants Bionomics Fast Track Designation to BNC210 for the acute treatment of social anxiety disorder and other anxiety related disorders
Nov 01, 2021: Bionomics Receives FDA clearance of IND for evaluation of BNC210 in a phase 2 social anxiety disorder PREVAIL study
Nov 01, 2021: Bionomics gets FDA approval for trial of social anxiety disorder treatment
Sep 20, 2021: Bionomics prepares BNC210 for start of phase 2 acute treatment of social anxiety disorder trial
Sep 09, 2021: Alpha Cognition to Webcast Live on ALPHA-1062 at Life Sciences Investor Forum September 16th
Sep 07, 2021: Alpha Cognition announces the acceptance of its US FDA investigational new drug application (IND) for lead candidate, ALPHA-1062 for mild to moderate Alzheimer’s Disease
Jul 08, 2021: Novamind selected as research site for Bionomics' PTSD clinical trial
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indications, 2022
Number of Products under Development by Indications, 2022 (Contd..1)
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Number of Products under Investigation by Universities/Institutes, 2022
Products under Investigation by Universities/Institutes, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Pipeline by 180 Life Sciences Corp, 2022
Pipeline by AlphaCognition Inc, 2022
Pipeline by AstraZeneca Plc, 2022
Pipeline by Bionomics Ltd, 2022
Pipeline by Bristol-Myers Squibb Co, 2022
Pipeline by DanPET AB, 2022
Pipeline by Epigen Biosciences Inc, 2022
Pipeline by Lupin Ltd, 2022
Pipeline by Merck & Co Inc, 2022
Pipeline by Neuro Bio Ltd, 2022
Pipeline by Serenity Bioworks Inc, 2022
Pipeline by SK Life Science Inc, 2022
Pipeline by Vanda Pharmaceuticals Inc, 2022
Dormant Products, 2022
Dormant Products, 2022 (Contd..1)
Dormant Products, 2022 (Contd..2)
Dormant Products, 2022 (Contd..3)
Discontinued Products, 2022

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Top 10 Indications, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022